Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Hendrik F. van Essen"'
Autor:
Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Abstract Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsie
Externí odkaz:
https://doaj.org/article/1763543d37b64f68b1819cf9d59358d5
Autor:
Erik van Dijk, Erik van Werkhoven, Rebecca Asher, Jennifer K. Mooi, David Espinoza, Hendrik F. van Essen, Harm van Tinteren, Nicole C. T. van Grieken, Cornelis J. A. Punt, Niall C. Tebbutt, Bauke Ylstra
Publikováno v:
van Dijk, E, van Werkhoven, E, Asher, R, Mooi, J K, Espinoza, D, van Essen, H F, van Tinteren, H, van Grieken, N C T, Punt, C J A, Tebbutt, N C & Ylstra, B 2022, ' Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer : A post hoc analysis of the randomized phase III-trial AGITG-MAX ', International Journal of Cancer, vol. 151, no. 7, pp. 1166-1174 . https://doi.org/10.1002/ijc.34061
International Journal of Cancer, 151(7), 1166-1174. Wiley-Liss Inc.
International Journal of Cancer, 151(7), 1166-1174. Wiley-Liss Inc.
The VEGF-A monoclonal antibody bevacizumab is currently recommended for first-line treatment of all metastatic colorectal cancer (mCRC) patients. Cost-benefit ratio and side-effects however necessitate patient selection. A large retrospective yet non
Autor:
Sabine C. Linn, Andreas Schneeweiss, Michael Hauptmann, Bauke Ylstra, Hendrik F. van Essen, Hans-Peter Sinn, Sebastian Aulmann, Frederik Marmé, Philip C. Schouten
Supplementary Table 1. Description of the study according to REMARK.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b206c04ea560cd83e3014ffed4e55fb1
https://doi.org/10.1158/1078-0432.22459140
https://doi.org/10.1158/1078-0432.22459140
Autor:
Sabine C. Linn, Andreas Schneeweiss, Michael Hauptmann, Bauke Ylstra, Hendrik F. van Essen, Hans-Peter Sinn, Sebastian Aulmann, Frederik Marmé, Philip C. Schouten
Purpose: Breast cancers in carriers of inactivating mutations of the BRCA1 gene carry a specific DNA copy-number signature (“BRCA1-like”). This signature is shared with cancers that inactivate BRCA1 through other mechanisms. Because BRCA1 is impo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eda9e8108cd05b8e32b4d3f7eae74c6
https://doi.org/10.1158/1078-0432.c.6524142
https://doi.org/10.1158/1078-0432.c.6524142
Autor:
Hedde D. Biesma, Tanya T. D. Soeratram, Karolina Sikorska, Irene A. Caspers, Hendrik F. van Essen, Jacqueline M. P. Egthuijsen, Aart Mookhoek, Hanneke W. M. van Laarhoven, Mark I. van Berge Henegouwen, Marianne Nordsmark, Donald L. van der Peet, Fabienne A. R. M. Warmerdam, Maud M. Geenen, Olaf J. L. Loosveld, Johanneke E. A. Portielje, Maartje Los, Daniëlle A. M. Heideman, Elma Meershoek-Klein Kranenbarg, Henk H. Hartgrink, Johanna van Sandick, Marcel Verheij, Cornelis J. H. van de Velde, Annemieke Cats, Bauke Ylstra, Nicole C. T. van Grieken
Publikováno v:
Gastric Cancer, 25, 3, pp. 640-651
Biesma, H D, Soeratram, T T D, Sikorska, K, Caspers, I A, van Essen, H F, Egthuijsen, J M P, Mookhoek, A, van Laarhoven, H W M, van Berge Henegouwen, M I, Nordsmark, M, van der Peet, D L, Warmerdam, F A R M, Geenen, M M, Loosveld, O J L, Portielje, J E A, Los, M, Heideman, D A M, Meershoek-Klein Kranenbarg, E, Hartgrink, H H, van Sandick, J, Verheij, M, van de Velde, C J H, Cats, A, Ylstra, B & van Grieken, N C T 2022, ' Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer : a post hoc analysis of the D1/D2 and CRITICS trials ', Gastric Cancer, vol. 25, no. 3, pp. 640-651 . https://doi.org/10.1007/s10120-022-01280-2
Gastric Cancer, 25(3), 640-651. Springer Japan
Gastric Cancer, 25, 640-651. SPRINGER
Gastric Cancer, 25, 640-651
Biesma, H D, Soeratram, T T D, Sikorska, K, Caspers, I A, van Essen, H F, Egthuijsen, J M P, Mookhoek, A, van Laarhoven, H W M, van Berge Henegouwen, M I, Nordsmark, M, van der Peet, D L, Warmerdam, F A R M, Geenen, M M, Loosveld, O J L, Portielje, J E A, Los, M, Heideman, D A M, Meershoek-Klein Kranenbarg, E, Hartgrink, H H, van Sandick, J, Verheij, M, van de Velde, C J H, Cats, A, Ylstra, B & van Grieken, N C T 2022, ' Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer : a post hoc analysis of the D1/D2 and CRITICS trials ', Gastric Cancer, vol. 25, no. 3, pp. 640-651 . https://doi.org/10.1007/s10120-022-01280-2
Gastric Cancer, 25(3), 640-651. Springer Japan
Gastric Cancer, 25, 640-651. SPRINGER
Gastric Cancer, 25, 640-651
Background Epstein–Barr virus positivity (EBV+) and microsatellite instability (MSI-high) are positive prognostic factors for survival in resectable gastric cancer (GC). However, benefit of perioperative treatment in patients with MSI-high tumors r
Autor:
Lisanne E. Nijman, Cornelis J A Punt, Khalid El Makrini, Erik van Dijk, Bauke Ylstra, Louis Vermeulen, Rebecca C. Fitzgerald, Daniël M. Miedema, Jurriaan B. Tuynman, Tom van den Bosch, Jan Paul Medema, Geert J. P. L. Kops, Hendrik F. van Essen, Michiel Boekhout, Joris H. Hageman, Kristiaan J. Lenos, Hugo J. Snippert, Nico Lansu
Publikováno v:
Nature communications, 12(1):3188. Nature Publishing Group
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Nature Communications, 12(1). Nature Publishing Group
van Dijk, E, van den Bosch, T, Lenos, K J, el Makrini, K, Nijman, L E, van Essen, H F B, Lansu, N, Boekhout, M, Hageman, J H, Fitzgerald, R C, Punt, C J A, Tuynman, J B, Snippert, H J G, Kops, G J P L, Medema, J P, Ylstra, B, Vermeulen, L & Miedema, D M 2021, ' Chromosomal copy number heterogeneity predicts survival rates across cancers ', Nature Communications, vol. 12, no. 1, 3188 . https://doi.org/10.1038/s41467-021-23384-6
Nature Communications, 12(1):3188. Nature Publishing Group
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Nature Communications, 12(1). Nature Publishing Group
van Dijk, E, van den Bosch, T, Lenos, K J, el Makrini, K, Nijman, L E, van Essen, H F B, Lansu, N, Boekhout, M, Hageman, J H, Fitzgerald, R C, Punt, C J A, Tuynman, J B, Snippert, H J G, Kops, G J P L, Medema, J P, Ylstra, B, Vermeulen, L & Miedema, D M 2021, ' Chromosomal copy number heterogeneity predicts survival rates across cancers ', Nature Communications, vol. 12, no. 1, 3188 . https://doi.org/10.1038/s41467-021-23384-6
Nature Communications, 12(1):3188. Nature Publishing Group
Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes. In contrast, intra-tumour heterogenei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c5aadebea81d9f17d09ab04b8e9c95
https://www.repository.cam.ac.uk/handle/1810/324542
https://www.repository.cam.ac.uk/handle/1810/324542
Autor:
Ida H. Hiemstra, Hilma J. van der Horst, Martine E.D. Chamuleau, A. Vera de Jonge, Margaretha G. M. Roemer, Tuna Mutis, Hendrik F. van Essen, Daniella R. A. I. Berry, Anne T. Gelderloos, Nathalie J. Hijmering, Sonja Zweegman, Daphne de Jong, Esther C.W. Breij
Publikováno v:
Blood Cancer Journal
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Blood cancer journal, 11(2):38. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
van der Horst, H J, de Jonge, A V, Hiemstra, I H, Gelderloos, A T, Berry, D R A I, Hijmering, N J, van Essen, H F, de Jong, D, Chamuleau, M E D, Zweegman, S, Breij, E C W, Roemer, M G M & Mutis, T 2021, ' Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment ', Blood cancer journal, vol. 11, no. 2, 38 . https://doi.org/10.1038/s41408-021-00430-6
Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from ne
Autor:
Madeleine C. van den Berg, Hendrik F. van Essen, Bauke Ylstra, François Rustenburg, Henk M.W. Verheul, Paul P. Eijk, Ruud H. Brakenhoff, Dennis Poel, Jens Voortman, Teresita Elhorst Benites, Elisabeth Bloemena, Marije R. Vergeer, Tineke E. Buffart, Rene Leemans, Daoud Sie
Publikováno v:
Poel, D, Rustenburg, F, Sie, D, van Essen, H F, Eijk, P P, Bloemena, E, Elhorst Benites, T, van den Berg, M C, Vergeer, M R, Leemans, R C, Buffart, T E, Ylstra, B, Brakenhoff, R H, Verheul, H M, Voortman, J & van den Berg, M C 2020, ' Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer ', Oral Oncology, vol. 109, 104851 . https://doi.org/10.1016/j.oraloncology.2020.104851
Oral Oncology, 109
Poel, D, Rustenburg, F, Sie, D, van Essen, H F, Eijk, P P, Bloemena, E, Elhorst Benites, T, van den Berg, M C, Vergeer, M R, Leemans, R C, Buffart, T E, Ylstra, B, Brakenhoff, R H, Verheul, H M & Voortman, J 2020, ' Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer ', Oral Oncology, vol. 109, 104851 . https://doi.org/10.1016/j.oraloncology.2020.104851
Oral Oncology, 109:104851. Elsevier Limited
Oral Oncology, 109
Poel, D, Rustenburg, F, Sie, D, van Essen, H F, Eijk, P P, Bloemena, E, Elhorst Benites, T, van den Berg, M C, Vergeer, M R, Leemans, R C, Buffart, T E, Ylstra, B, Brakenhoff, R H, Verheul, H M & Voortman, J 2020, ' Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer ', Oral Oncology, vol. 109, 104851 . https://doi.org/10.1016/j.oraloncology.2020.104851
Oral Oncology, 109:104851. Elsevier Limited
Item does not contain fulltext OBJECTIVES: The majority of patients with locally advanced larynx or hypopharynx squamous cell carcinoma are treated with organ-preserving chemoradiotherapy (CRT). Clinical outcome following CRT varies greatly. We hypot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8373762b5267f262379d583ae347085b
https://hdl.handle.net/1871.1/e761f5b0-c04f-4d38-b247-90b8e2a11bd8
https://hdl.handle.net/1871.1/e761f5b0-c04f-4d38-b247-90b8e2a11bd8
Autor:
Bauke Ylstra, Paul P. Eijk, Erik Thunnissen, Oscar Krijgsman, Nicole W. J. Bulkmans, Julien Vincenten, Daoud Sie, Egbert F. Smit, Birgit I. Lissenberg-Witte, Hendrik F. van Essen
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0225733 (2019)
PLoS ONE
PLoS ONE
Multiple tumors in patients are frequently diagnosed, either synchronous or metachronous. The distinction between a second primary and a metastasis is important for treatment. Chromosomal DNA copy number aberrations (CNA) patterns are highly unique t